PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China. Electronic address: jszfc@vip.sina.com.\', \'Hubei Provincial Center for Diseases Control and Prevention, Wuhan, China.\', \'National Institute for Food and Drug Control, Dongcheng, Beijing, China.\', \'Clinical Trial Center, Zhongnan Hospital of Wuhan University, Wuhan, China.\', \'Beijing Institute of Microbiology and Epidemiology, State Key Laboratory of Pathogen and Biosecurity, Beijing, China.\', \'Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China.\', \'NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China.\', \'CanSino Biologics, Tianjin, China.\', \'Shanghai Canming Medical Technology, Shanghai, China.\', \'Clinical Trial Center, Zhongnan Hospital of Wuhan University, Wuhan, China. Electronic address: wangxinghuan@whu.edu.cn.\', \'Beijing Institute of Biotechnology, Academy of Military Medical Sciences, Beijing, China. Electronic address: cw0226@foxmail.com.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0140-6736(20)31605-610.1016/S0140-6736(20)31605-6
?:doi
?:hasPublicationType
?:journal
  • Lancet (London, England)
is ?:pmid of
?:pmid
?:pmid
  • 32702299
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.
?:type
?:year
  • 2020

Metadata

Anon_0  
expand all